Kura Oncology (KURA): Persistent Losses Undercut Rapid 42.7% Revenue Growth Narrative [Yahoo! Finance]
Kura Oncology, Inc. (KURA)
Last kura oncology, inc. earnings: 2/25 04:03 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.kuraoncology.com/investor-relations
Company Research
Source: Yahoo! Finance
However, the company remains unprofitable with losses increasing at a 15.3% annual rate over the past five years. Despite this high growth outlook, profit margins have not improved and analysts expect losses to continue over the next three years. Investors face a classic trade-off here: rapid revenue growth against persistent losses and profitability concerns. See our full analysis for Kura Oncology. Next, we will see how these headline results measure up against the broader narrative—whether the numbers match the story investors have been telling or point to a shift in sentiment. See what the community is saying about Kura Oncology NasdaqGS:KURA Earnings & Revenue History as at Nov 2025 Cash Reserves Shrink as Losses Deepen Kura Oncology's cash position dropped from $727.4 million at the end of 2024 to $630.7 million by June 2025, while net losses increased from $50.8 million in Q2 2024 to $66.1 million a year later. Bears argue that these widening losses and a declinin
Show less
Read more
Impact Snapshot
Event Time:
KURA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KURA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KURA alerts
High impacting Kura Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
KURA
News
- Kura Oncology (NASDAQ:KURA) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..MarketBeat
- Kura Oncology: A Cautious Buy [Seeking Alpha]Seeking Alpha
- Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia [Yahoo! Finance]Yahoo! Finance
- Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid LeukemiaGlobeNewswire
- Kura Oncology: Expect Volatility Following Ziftomenib Phase 1b Data [Seeking Alpha]Seeking Alpha
KURA
Earnings
- 11/4/25 - Miss
KURA
Sec Filings
- 12/2/25 - Form 8-K
- 11/14/25 - Form 144
- 11/14/25 - Form 4
- KURA's page on the SEC website